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overlap of modular additions, minimizing the risk for dis-
connection or malalignment of components.
The PowerLink System has a unique delivery mechanism.
It requires only one vessel to be exposed. The contralateral
limb is deployed with a 9F introducer sheath. Through the
use of a proprietary catheter, an Amplatz wire is delivered into
the aorta while the contralateral limb wire is passed through
the contralateral 9F introducer sheath (Fig 3).
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Clinical and design update on the development
and testing of a one-piece, bifurcated, polytetra-
fluoroethylene endovascular graft for abdominal
aortic aneurysm exclusion: The Endologix device
Rodney A. White, MD, Torrance, Calif
Continued success and expanding use of endovascular prostheses to manage aortic aneurysms has encouraged devel-
opment of novel prototypes that offer advantages for low-profile delivery of durable devices. The Endologix device,
currently being acquired by CR Bard, Incorporated, is a new, one-piece self-expanding polytetrafluoroethylene pros-
thesis that offers an alternative to current modular and fabric devices. Although only preliminary U.S. and expand-
ing European experiences are available, the unique features of this prosthesis appear to offer an appealing alternative.
(J Vasc Surg 2001;33:S154-6.)
Fig 1. Endologix device consists of self-expanding stainless steel
frame with thin polytetrafluoroethylene covering.
THE ENDOLOGIX DEVICE
This is a report on a new-generation abdominal aortic
aneurysm endoluminal graft. The PowerLink System con-
sists of a single wire that is shaped and interconnected
without the use of sutures. The cage is made of self-
expanding stainless steel. Fixation is achieved by a combi-
nation of oversizing of the graft at the proximal neck and
a relatively long main body that provides longitudinal sup-
port and minimizes the potential for migration (Fig 1).
The device is available in both an infrarenal and a
suprarenal configuration that has 2 cm of open wire per-
mitting suprarenal fixation (Fig 2).
The wire form endoskeleton is covered by an
extremely strong, thin-walled polytetrafluoroethylene
graft. This allows the prosthesis to be delivered in a 20F or
21F catheter. The thin-walled material minimizes intralu-
minal narrowing caused by crimping of the graft lining,
allowing the PowerLink System to treat a wider variety of
neck and limb diameters with two size devices, 25- and
28-mm necks and 16-mm limbs. Proximal cuffs and limb
extensions permit the operator to customize the device to
an individual patient’s anatomy. The long segment of the
proximal aortic body and iliac limbs permits significant
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Fig 2. Infrarenal (left) and suprarenal (right) configurations of device.
Fig 3. See legend on next page.
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CURRENT STATUS
The PowerLink System has completed phase I of a
Food and Drug Administration-approved trial in the
United States, with 19 patients being successfully treated in
two centers. Of the 19 patients, there were 16 males and 3
females with an age range of 64 to 83 years. There were no
conversions to open surgical repair, deaths, or major com-
plications. There was one unresolved endoleak at discharge.
Data from the 1-month follow-up examinations with
ultrasound scanning and x-ray evaluation have been
received for all 19 patients. There were no reports of
endoleaks by ultrasound scanning, and there was one
reported complication of a local hematoma.
Six-month follow-up examinations with computed
tomography scans (with and without contrast) have been
received for 15 patients. There were no reports of
endoleaks, with three patients exhibiting five complica-
tions. The complications were back pain and loss of con-
sciousness resulting from a fall in a patient with Parkinson’s
disease, transient ischemic attack, symptomatic arrhyth-
mia, and anemia.
One patient underwent a secondary proximal cuff
implant to address an endoleak that was present at dis-
charge. This was a minor leak, and no treatment was
planned at the time the patient was discharged. The
patient underwent ultrasound scanning and an x-ray
examination at 1 month, and no evidence of an endoleak
was noted. The patient was scheduled for a follow-up
computed tomography scan at 3 months, and an endoleak
that required intervention was noted. A proximal cuff was
implanted with resolutions of the leak.
The phase II trials began in the United States in July
2000 in 12 centers. The device has also been evaluated in
more than 100 patients in several European centers. The
initial data support continued use of the device and have
led to permission to affix the Conformité Européene mark.
Submitted Jun 13, 2000; accepted Aug 15, 2000.
Fig 3. An outer sheath covers entire body of Endologix device. Limbs are each covered by thin sleeve, and two sleeves are loaded within
larger outer sheath. Sleeve covering contralateral limb has wire attached that enables deployment of this limb with the following deploy-
ment sequence: A, Deployment catheter is introduced into aorta above bifurcation, and outer sheath is retracted, exposing the two com-
pressed limbs. Notice wire attached to contralateral limb sleeve. B, Entire device is brought caudal, monitoring position of top of cage
in relation to renal arteries. C, Main body is partially deployed by pushing off front sheath, deploying main body distal to proximal. D,
Before main body deployment is completed, final device positioning is accomplished, and contralateral limb is deployed by pulling limb
cover wire. Limb cover and wire are removed by contralateral 9F sheath. E, Main body is fully deployed. F, Ipsilateral limb is deployed,
and the deployment catheter is removed.
Fig 4. Exclusion of infrarenal abdominal aortic aneurysm 24 hours after deployment with 6-month follow-up computed tomography
imaging.
